YME1L1 Protein
Overview
YME1L1 (YME1 Like 1 ATP-Dependent Protease) is a conserved serine protease localized to the inner mitochondrial membrane. This protein functions as a key component of mitochondrial proteostasis, maintaining the integrity and function of the mitochondrial compartment through selective protein degradation. YME1L1 belongs to the AAA+ (ATPases Associated with diverse cellular Activities) protease family and represents the mammalian ortholog of yeast YME1, sharing structural and functional conservation across eukaryotic species. The protein is encoded by the YME1L1 gene located on chromosome 10q24.33 in humans.
Function and Biology
YME1L1 operates as an ATP-dependent protease embedded in the inner mitochondrial membrane, where it regulates the proteolytic degradation of damaged, misfolded, or surplus mitochondrial proteins. The protein contains several critical functional domains: a transmembrane domain for inner membrane anchoring, an AAA+ ATPase domain responsible for ATP hydrolysis-driven mechanical force generation, and a serine protease domain that performs the actual proteolytic cleavage. This dual enzymatic architecture allows YME1L1 to unfold substrate proteins using ATP energy and subsequently cleave them into smaller peptide fragments for further degradation by the proteasome or degradation by other proteases.
...YME1L1 Protein
Overview
YME1L1 (YME1 Like 1 ATP-Dependent Protease) is a conserved serine protease localized to the inner mitochondrial membrane. This protein functions as a key component of mitochondrial proteostasis, maintaining the integrity and function of the mitochondrial compartment through selective protein degradation. YME1L1 belongs to the AAA+ (ATPases Associated with diverse cellular Activities) protease family and represents the mammalian ortholog of yeast YME1, sharing structural and functional conservation across eukaryotic species. The protein is encoded by the YME1L1 gene located on chromosome 10q24.33 in humans.
Function and Biology
YME1L1 operates as an ATP-dependent protease embedded in the inner mitochondrial membrane, where it regulates the proteolytic degradation of damaged, misfolded, or surplus mitochondrial proteins. The protein contains several critical functional domains: a transmembrane domain for inner membrane anchoring, an AAA+ ATPase domain responsible for ATP hydrolysis-driven mechanical force generation, and a serine protease domain that performs the actual proteolytic cleavage. This dual enzymatic architecture allows YME1L1 to unfold substrate proteins using ATP energy and subsequently cleave them into smaller peptide fragments for further degradation by the proteasome or degradation by other proteases.
YME1L1 functions within the broader context of the mitochondrial unfolded protein response (mtUPR) and OPA1-like (OPA1) proteolysis regulation. One of its major roles involves processing and maintaining OPA1 (Optic Atrophy 1) levels, a dynamin-related GTPase critical for mitochondrial inner membrane organization and cristae structure. Through controlled proteolysis of OPA1, YME1L1 influences mitochondrial morphodynamics, including fusion and fission processes. Additionally, YME1L1 participates in the degradation of membrane proteins damaged by reactive oxygen species (ROS) and assists in removing oxidatively damaged components that accumulate during mitochondrial stress.
Role in Neurodegeneration
YME1L1 dysfunction has emerged as a significant contributor to multiple neurodegenerative diseases. In Alzheimer's disease, impaired mitochondrial protein quality control—including YME1L1 activity—correlates with amyloid-beta accumulation, tau pathology, and progressive neuronal loss. Mitochondrial dysfunction driven by defective YME1L1-mediated proteolysis exacerbates cellular bioenergetic failure and compromises synaptic maintenance in vulnerable neuronal populations.
In Parkinson's disease, YME1L1 dysfunction contributes to α-synuclein accumulation and mitochondrial fragmentation. Compromised YME1L1 activity reduces the cell's capacity to eliminate damaged mitochondrial proteins, particularly those modified by post-translational oxidation, promoting the formation of toxic protein aggregates and triggering dopaminergic neurodegeneration.
Mutations or reduced expression of YME1L1 are associated with dominant optic atrophy, a condition characterized by progressive degeneration of retinal ganglion cells. This indicates particular vulnerability of neurons with high metabolic demands to YME1L1 deficiency. Evidence also suggests YME1L1 involvement in ALS and other neurodegenerative conditions characterized by mitochondrial stress and impaired proteostasis.
Molecular Mechanisms
YME1L1 contributes to neurodegeneration through several interconnected mechanisms. Its impaired activity diminishes the capacity for mitochondrial protein quality control, allowing accumulation of misfolded and aggregation-prone proteins. This directly compromises mitochondrial function, reducing ATP production and exacerbating cellular energy deficits—particularly critical in energy-demanding neurons.
YME1L1-mediated OPA1 processing dysregulation disrupts cristae architecture and mitochondrial dynamics, promoting excessive fragmentation. Fragmented mitochondria exhibit reduced bioenergetic efficiency and impaired removal through mitophagy, leading to progressive accumulation of dysfunctional organelles and cellular dysfunction.
Furthermore, defective YME1L1 activity impairs clearance of ROS-damaged mitochondrial components, amplifying oxidative stress and triggering mitochondrial-mediated apoptosis pathways, particularly through BAX/BAK activation and cytochrome c release.
Clinical and Research Significance
YME1L1 represents a therapeutic target of increasing interest in neurodegeneration research. Understanding its regulation and enhancing its activity may provide novel interventions for multiple neurodegenerative diseases. Current research focuses on characterizing YME1L1 substrate specificity, developing selective activators, and investigating YME1L1 genetic variants as susceptibility factors in common neurodegenerative diseases.
- OPA1 (Optic Atrophy 1)
- Mitochondrial Proteostasis
- Mitochondrial Unfolded Protein Response (mtUPR)
- AAA+ Proteases
- Mitochondrial Dynamics
- Mitop